DOCSLIB.ORG

Serum Immunoregulatory Proteins As Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab Yoshinobu Koguchi1, Helena M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Serum Immunoregulatory Proteins As Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab Yoshinobu Koguchi1, Helena M Cancer Microenvironment and Immunology Research Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab Yoshinobu Koguchi1, Helena M. Hoen1, Shelly A. Bambina1, Michael D. Rynning2, Richard K. Fuerstenberg2, Brendan D. Curti1, Walter J. Urba1, Christina Milburn3, Frances Rena Bahjat3, Alan J. Korman3, and Keith S. Bahjat1 Abstract Treatment with ipilimumab improves overall survival (OS) [log10 CXCL11: HR, 1.88; 95% confidence interval (CI), 1.14– in patients with metastatic melanoma. Because ipilimumab 3.12; P ¼ 0.014; and log10 sMICA quadratic effect P ¼ 0.066; targets T lymphocytes and not the tumor itself, efficacy may sMICA ( 247 vs. 247): HR, 1.75; 95% CI, 1.02–3.01]. Mul- be uniquely sensitive to immunomodulatory factors present at tivariate analysis of an independent ipilimumab-treated cohort the time of treatment. We analyzed serum from patients with confirmed the association between log10 CXCL11 and OS (HR, metastatic melanoma (247 of 273, 90.4%) randomly assigned 3.18; 95% CI, 1.13–8.95; P ¼ 0.029), whereas sMICA was less to receive ipilimumab or gp100 peptide vaccine. We quantified strongly associated with OS [log10 sMICA quadratic effect P ¼ candidate biomarkers at baseline and assessed the association 0.16; sMICA (247 vs. 247): HR, 1.48; 95% CI, 0.67–3.27]. of each using multivariate analyses. Results were confirmed in High baseline CXCL11 and sMICA were associated with poor an independent cohort of similar patients (48 of 52, 92.3%) OS in patients with metastatic melanoma after ipilimumab treated with ipilimumab. After controlling for baseline covari- treatment but not vaccine treatment. Thus, pretreatment ates, elevated chemokine (C-X-C motif) ligand 11 (CXCL11) CXCL11 and sMICA may represent predictors of survival benefit and soluble MHC class I polypeptide–related chain A (sMICA) after ipilimumab treatment as well as therapeutic targets. Cancer were associated with poor OS in ipilimumab-treated patients Res; 75(23); 5084–92. Ó2015 AACR. Introduction received ipilimumab monotherapy achieved a 28.4% four-year OS rate (6). Despite the success of ipilimumab, the majority of the Ipilimumab is a human monoclonal antibody targeting CTLA- patients on this study died as a consequence of melanoma. With 4 (cytotoxic T lymphocyte antigen-4). CTLA-4 is expressed on an increasing number of treatment options available and activated T cells, has structural similarities to the costimulatory increased use of targeted therapies, predictive biomarkers that molecule CD28, and binds to the same ligands as CD28 albeit identify those patients most likely to benefit from a specific with higher affinity. Binding of CTLA-4 to CD80/CD86 inhibits T- treatment are needed (7, 8). cell activation by limiting IL2 production and expression of the Unlike traditional cancer therapies, immunotherapeutics act IL2 receptor (CD25; ref. 1). Ipilimumab prevents CTLA-4 from primarily upon cells of the immune system. The requirement for binding its ligands, thus promoting activation of effector T cells the immune system as a third-party mediator of the drug's activity via prolonged CD28 signaling (2). In addition, anti-CTLA-4 suggests the balance of positive and negative regulators of the antibodies can deplete intratumoral regulatory T cells, subverting immune response at the time of therapy may be a critical deter- yet another mechanism of immunosuppression (3). minant of efficacy for any immunotherapy. Cytokines, chemo- Ipilimumab improved overall survival (OS) in patients with kines, and soluble receptors regulate the survival, activity, and metastatic melanoma in a randomized, double-blinded phase III location of immune effector cells and thus represent potential clinical trial (4, 5). Patients with metastatic melanoma who players in determining drug efficacy. Of particular interest are soluble factors involved in the recruitment and regulation of effector T cells representing the most readily measurable clinical 1Earle A. Chiles Research Institute, Providence Cancer Center, Port- biomarkers. 2 3 land, Oregon. R&D Systems, Minneapolis, Minnesota. Bristol-Myers To identify candidate soluble factor(s) predictive of improved Squibb, Redwood City, California. survival following ipilimumab treatment, we analyzed pretreat- Note: Supplementary data for this article are available at Cancer Research ment sera from treatment (ipilimumab) and "active control" Online (http://cancerres.aacrjournals.org/). (gp100 vaccine) patients from the pivotal phase III clinical trial Corresponding Author: Keith S. Bahjat, Earle A. Chiles Research Institute, of ipilimumab (4) for a variety of factors and correlated their Providence Cancer Center, 4805 NE Glisan Street, 2N83, Portland, OR 97213. levels with OS. A hypothesis-guided panel of candidate biomar- Phone: 503-215-7229; Fax: 503-215-6841; E-mail: [email protected] kers was selected, including biomarkers previously reported to doi: 10.1158/0008-5472.CAN-15-2303 associate with response to ipilimumab. Each analyte was assessed Ó2015 American Association for Cancer Research. in univariate and multivariate models for its correlation with OS. 5084 Cancer Res; 75(23) December 1, 2015 Downloaded from cancerres.aacrjournals.org on September 27, 2021. © 2015 American Association for Cancer Research. Immunoregulatory Proteins Predict Outcome of Ipilimumab Treatment Correlative biomarkers identified in the initial screen were further phase III trial, differences within treatment group were of primary validated by testing sera from an independent cohort of ipilimu- interest and thus tested in separate models. Survival was defined mab-treated patients at our institution. as time from beginning of ipilimumab treatment to date of death, censoring at date of last follow-up. To calculate median follow-up time, deaths were censored. Patients and Methods Univariate survival analysis was performed for each treatment Clinical trials subgroup using Cox proportional hazards regression. Effects of Detailed information regarding the phase III clinical trial of CXCL11, sMICA, sMICB, sCD25, VEGF, absolute lymphocyte ipilimumab (NCT00094653) was reported elsewhere (4). Briefly, counts (ALC), tumor burden, and effect of LDH [ vs. > upper patients with metastatic melanoma having failed at least one prior limit of normal (ULN)] were shown. Models of quadratic effects therapy that may have included IL2, dacarbazine, and/or temo- to examine possible nonlinear effects and models of linear effects zolomide were enrolled excluding those with ocular melanoma. of continuous variables were tested. When the quadratic effect was à þ All patients were HLA-A 0201 as the restricting element for the not significant or the linear effect was more strongly significant, gp100 peptides used. All ipilimumab-treated patients received main effects model results were reported. For sMICA and VEGF, ipilimumab alone at 3 mg/kg every 3 weeks for 4 treatments. In quadratic effect was significant in some models. To present an HR, the gp100 group, patients received two peptides (1 mg each), results are also reported for a categorized variable, with the cutoff injected subcutaneously as an emulsion with incomplete Freund's point determined as the quintile where a threshold effect was adjuvant (Montanide ISA-51). Peptide injections were given observed in the phase III trial. Kaplan–Meier plots used for immediately after 90-minute intravenous infusion of placebo. determining cutoff points are shown in Supplementary Fig. S1. Tumor burden was assessed by the treating physician as previ- In multivariate analyses, model results of the remaining variables ously described (4). (other than sMICA), however, are from the model containing the Serum samples were also obtained from patients treated on an continuous form of the variable with the quadratic effect. Con- expanded access program at the Earle A. Chiles Research Institute tinuous measures were approximately log normal and analyzed as (EACRI cohort). Detailed information regarding this Compas- log10-transformed. sionate Use Trial for Unresectable Melanoma with Ipilimumab is In multivariate analysis of OS, Cox proportional hazards available elsewhere (NCT00495066). All patients received ipili- regression was used to test effects of biomarker candidates on mumab alone (3 or 10 mg/kg every 3 weeks for 4 treatments) with survival after controlling for other biomarkers and baseline no exclusions for ocular primary melanomas or HLA type. patient characteristics. Only CXCL11 and sMICA were included, All patients provided written informed consent and all studies as they were significant in univariate survival models of the were carried out in accordance with the Declaration of Helsinki ipilimumab group but not the gp100 group. Covariates in models under good clinical practice and Institutional Review Board for both studies were age, gender, ECOG status, prior immuno- approval. therapy, LDH, and ALC. Tumor burden was also included in multivariate model for the phase III trial cohort, but not the EACRI Serum cytokine analysis cohort as these data were not captured. Serum was collected and stored at À80 C. Chemokine (C-C Analyses were performed using SAS 9.3 (SAS Institute Inc.). motif) ligand 2 (CCL2), CCL3, CCL4, CCL8, CCL18, CCL26, Forest plots were prepared using Forest Plot Viewer (9) and edited chemokine (C-X-C motif) ligand (CXCL9), CXCL10, CXCL11, using Adobe Illustrator. GraphPad Prism was used for depicting CXCL13, and VEGF were measured using a bead-based multi- some
Load more

Recommended publications
  • Analysis of Carbohydrates and Glycoconjugates by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry: an Update for 2011–2012
    ANALYSIS OF CARBOHYDRATES AND GLYCOCONJUGATES BY MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS SPECTROMETRY: AN UPDATE FOR 2011–2012 David J. Harvey* Department of Biochemistry, Oxford Glycobiology Institute, University of Oxford, Oxford OX1 3QU, UK Received 19 June 2014; accepted 15 January 2015 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/mas.21471 This review is the seventh update of the original article published text. As the review is designed to complement the earlier work, in 1999 on the application of MALDI mass spectrometry to the structural formulae, etc. that were presented earlier are not analysis of carbohydrates and glycoconjugates and brings repeated. However, a citation to the structure in the earlier work coverage of the literature to the end of 2012. General aspects is indicated by its number with a prefix (i.e., 1/x refers to such as theory of the MALDI process, matrices, derivatization, structure x in the first review and 2/x to structure x the second). MALDI imaging, and fragmentation are covered in the first part Books, general reviews, and review-type articles directly of the review and applications to various structural types concerned with, or including, MALDI analysis of carbohydrates constitute the remainder. The main groups of compound are and glycoconjugates to have been published during the review oligo- and poly-saccharides, glycoproteins, glycolipids, glyco- period are listed in Table 1. Reviews relating to more specific sides, and biopharmaceuticals. Much of this material is presented aspects of MALDI analysis are listed in the appropriate sections. in tabular form. Also discussed are medical and industrial applications of the technique, studies of enzyme reactions, and II.
    [Show full text]
  • Annuaire Officiel De L'union Europøenne
    Donnes à jour au 23 dcembre 2004 Annuaire officiel de l’Union europenne 2005 UNION EUROPÉENNE Avis au lecteur Cette publication parat une fois par an, en trois langues: allemand, anglais et franÅais. Son contenu reprend les organigrammes des institutions, organes, agences et organismes de l’Union europenne jusqu’au niveau des responsables des entits oprationnelles de base. Une version lectronique, actualise rgulirement, peut Þtre consulte sur l’internet via le serveur Europa (http://europa.eu.int/idea). En raison du nombre et de la complexit des intituls des fonctions à grer dans les diffrentes versions linguistiques, il ne nous est pas possible, pour l’instant, de prendre en compte les variantes fminin/masculin de celles-ci. Nous avons donc opt pour une dnomination unique à considrer comme neutre. Europe Direct est un service destin à vous aider à trouver des rponses aux questions que vous vous posez sur l’Union europenne. Un nouveau numro unique gratuit: 000 800 6 7 8 9 10 11 De nombreuses autres informations sur l’Union europenne sont disponibles sur l’internet via le serveur Europa (http://europa.eu.int). Une fiche bibliographique figure à la fin de l’ouvrage. Luxembourg: Office des publications officielles des Communauts europennes, 2005 ISBN 92-78-40259-1 Communauts europennes, 2005 Reproduction autorise, moyennant mention de la source Printed in Luxembourg IMPRIM SUR PAPIER BLANCHI SANS CHLORE Table des matires Prsentation des institutions de l’Union europenne .............................. V Renseignements pratiques ...................................................... XVII ˆ Adresses postales des institutions . ........................................ XIX ˆ Liste des btiments . ........................................................ XXIII ˆ Plans d’accs aux btiments .
    [Show full text]
  • Ironman Nice 22/06/08
    IRONMAN NICE 22/06/08 Rank StNr FAMILY NAME FISRT NAME NAT SEXE CAT Rk/CAT SWIM T1 BIKE T2 RUN FINISH Club 1 1 ZAMORA PEREZ Marcel ESP M MPRO 1 0:50:09 00:02:33 4:54:01 00:02:14 2:45:06 8:34:03 Cn Barcelona 2 2 FAURE Hervé FRA M MPRO 2 0:50:37 00:02:44 4:53:23 00:02:42 2:52:14 8:41:40 3 3 BRINGER Patrick FRA M MPRO 3 0:50:17 00:02:31 4:53:54 00:02:14 2:56:04 8:45:00 Montluçon Triathlon 4 18 JEULAND José FRA M MPRO 4 0:53:52 00:02:52 4:52:51 00:02:53 3:01:06 8:53:34 Team Girs 5 5 BEKE Rutger BEL M MPRO 5 0:52:43 00:02:52 4:51:10 00:02:17 3:06:09 8:55:11 Tdl 6 10 AIGROZ Mike SUI M MPRO 6 0:50:02 00:02:44 4:44:26 00:02:37 3:16:54 8:56:43 Sartrouville Triathlon 7 9 MAJOR Jozsef HUN M MPRO 7 0:59:03 00:03:49 4:55:46 00:02:22 2:56:45 8:57:45 Szechenyi Ese 8 405 LANDON Damien FRA M M25 1 0:50:25 00:03:04 5:04:05 00:02:58 3:10:24 9:10:56 Tri Saint Amand Dun 18 9 808VAN ROOSBROECK Jef BEL M M30 11:05:2400:05:04 5:01:23 00:03:20 2:57:23 9:12:34 10 6 LE FLOCH Xavier FRA M MPRO 8 0:50:12 00:02:53 5:01:35 00:02:37 3:15:32 9:12:49 Triathl'aix 11 524 BLANKENFULAND Daniel GER M M25 2 0:52:41 00:03:20 5:01:08 00:03:22 3:13:44 9:14:15 Llg Wonnegau 12 17 JALABERT Laurent FRA M M35 1 1:06:50 00:05:22 4:45:29 00:03:17 3:13:36 9:14:34 Montauban T.c 13 855 HOUZELLE Fabrice FRA M M30 2 1:01:38 00:04:02 5:05:04 00:03:19 3:03:29 9:17:32 As Libourne Triathlon 14 363 RICHTER Stefan GER M M18 1 0:51:11 00:03:31 4:58:26 00:02:59 3:21:32 9:17:39 Gealan Triteam Ifl Hof 15 334 GUILLAUME Romain FRA M M18 2 0:50:03 00:03:05 4:53:38 00:02:47 3:29:51 9:19:24 Beaune Monnot
    [Show full text]
  • Marathon Medoc 2017
    Rq_Export_Classement_Excel_1 CLT TEMPS DOS NOM PRENOM SEXE CLAS SEXE CAT CLAS CAT 1 02:27:06 1 GUIBAULT THIERRY H 1 V1H 1 2 02:33:11 6924 BENICHOU THOMAS H 2 SEH 1 3 02:35:20 6920 BAUDRY NICOLAS H 3 SEH 2 4 02:39:11 4888 WILMS ROBERT H 4 SEH 3 5 02:40:28 2 CHARNAY SEBASTIEN H 5 V1H 2 6 02:40:40 6617 BRISSE CLEMENT H 6 SEH 4 7 02:41:56 7042 RIBEIRO LIONEL H 7 SEH 5 8 02:43:14 6912 MULOT CYRILLE H 8 V1H 3 9 02:43:45 7040 PAJOT JOHANNICK H 9 V1H 4 10 02:44:13 8108 VERRIER SEBASTIEN H 10 SEH 6 11 02:45:24 4 DUFFAU STEFAN H 11 V1H 5 12 02:46:04 2832 LE QUERNEC FABRICE H 12 SEH 7 13 02:46:09 7038 MORVAN CHRISTOPHE H 13 V1H 6 14 02:46:23 7307 LERAY CHRISTOPHE H 14 V1H 7 15 02:47:30 7286 ETIENNE GAYLORD H 15 SEH 8 16 02:47:49 5 PALA LAURENT H 16 SEH 9 17 02:48:09 6913 GROUSSIN ANTOINE H 17 V1H 8 18 02:49:14 7025 CIBROT JEROME H 18 SEH 10 19 02:49:58 7411 BRUNEAU YVES H 19 V2H 1 20 02:50:03 6917 REY CHRISTOPHE H 20 V1H 9 21 02:50:41 7028 DESTRADE ERIC H 21 V1H 10 22 02:50:41 7036 HAMON FREDERIC H 22 V1H 11 23 02:52:27 7992 CAMPET PASCAL H 23 V2H 2 24 02:53:04 7475 FONTAINE BERNARD H 24 V2H 3 25 02:53:42 7180 DUMONTEIL CEDRIC H 25 V1H 12 26 02:54:23 7372 ESCALLE LAURENT H 26 SEH 11 27 02:55:57 6584 CLAEYSSENS NOEMIE F 1 SEF 1 28 02:56:28 7996 MORERE CHRISTOPHE H 27 V1H 13 29 02:56:38 7444 FERREIRA JOSEPH H 28 V1H 14 30 02:56:42 6911 DILMI LUDOVIC H 29 V2H 4 31 02:57:19 5397 CABRERA DAVID H 30 SEH 12 32 02:57:39 7041 PIVETEAU PASCAL H 31 V2H 5 33 02:58:32 7 VASSEUR NATHALIE F 2 V2F 1 34 02:58:48 7589 PLANEL EDOUARD H 32 SEH 13 35 02:59:00 51 LANOELLE
    [Show full text]
  • Biofilesheadinglist.Pdf
    Biography File Headings Surname Location Cross Reference Cross Reference Cross Reference Cross Reference A Aagaard Aalto McHenry Aavang Greenwood TWP / Woodstock Aavang Photos Greenwood TWP / Woodstock Abando Abbamonto Cary Abbey Abbot see Abbott Abbot(t) Algonquin TWP Abbott Greenwood TWP / Woodstock Abbott Marengo Abbs Abboud Aibel Aibell Abercrombie Marengo see Aicox Abernathy Aberst Abernethy Ablinger Abolins Abi Abner Abraham Abraham Coral TWP Abraham Marengo Abraham Seneca TWP Abrahamsen Abramat Abramovitz Abrath Abromaitis Abdullai Abt Achey Achtenfeld Ackeman(n) Acker Harvard Acker Acker Marengo Ackeret Ackerman Ackerman Crystal Lake Ackerson Ackerson Seneca TWP Ackert Ackley Ackman Acosta Acox Marengo Acred Adair Adam Adamek Algonquin Adams Adams Alden Adams Chemung TWP Adams Coral TWP Adams Marengo/Greenwood Adams Harvard Adams Hebron TWP Adams Huntley Adams McHenry TWP Adams Richmond Adamson Union, Huntley, Marengo Adamy Addison McHenry Addy Adler Adolphs Adolphsen Adomaitis 1 Adolphus Adriance Crystal Lake Adrain Adridge Adrience Adsit Aerkfritz Aeverman McHenry Aevermann Cary Afeld, R McHenry Affeldt Affield Agard Affronti Aggen Agnes Agnew Aguirre Ahearn Ahlberg Ahlman Ahlstram Ahnger Ahrens Ahrens Alden Ahrens Cary Ahrens Harvard Ahrens Hebron Ahrens Huntley Ahrens Marengo Aicher Aicher McHenry Aicox Aiello Aikin Ainger Ainsalu Ainsworth Aissen Akerberg Akerburg Akerman Akers Akinner Akins Alanson Albanese Albee Alberding Albers Albert Alberth Alberts Albertsen Albertson Albertus Alberty See Alberti Alberti(y) Alden Albrecht Crystal Lake Albery Alberty Albrecht Grafton TWP Albold Albrecht Marengo/Union Albrecht McHenry Albrecht Woodstock Albretch See Albrecht Alberth Albright Albright Woodstock Albro(w) Seneca Alcock Alden Alcumbrac Alderman Aldersen Alderson Bull Valley Aldred 2 Aldrich Aldridge Alex Alexakos Alexander Alexander Crystal Lake Alexander Fox R.
    [Show full text]
  • Cranfield University Thiruchelvam Thanaraj Understanding the Changes in Sri Lankan Mango Fruits During Postharvest Ripening
    CRANFIELD UNIVERSITY THIRUCHELVAM THANARAJ UNDERSTANDING THE CHANGES IN SRI LANKAN MANGO FRUITS DURING POSTHARVEST RIPENING CRANFIELD HEALTH Plant Science Laboratory Ph.D THESIS 2010 ii CRANFIELD UNIVERSITY Cranfield Health Plant Science Laboratory Ph.D THESIS Academic Years: 2006-2010 THIRUCHELVAM THANARAJ UNDERSTANDING THE CHANGES IN SRI LANKAN MANGO FRUITS DURING POSTHARVEST RIPENING Supervisor: Dr. Leon A. Terry February 2010 This thesis is submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy © Cranfield University, 2010. All rights reserved. No part of this publication may be reproduced without the written permission of the copyright holder. T.Thanaraj Cranfield University Ph.D Thesis 2010 i ABSTRACT This is the first study to be carried out which describes changes in biochemical profile of both pre- and post-climacteric Sri Lankan mango fruits. Chemometric analysis revealed that spatial distribution of biochemical compounds between peel and pulp was the major discriminatory factor during maturation; whereas fully mature mango fruit contained the highest concentration of starch and lowest concentration of acids. Since these combined variables also responsible for the final quality of ripe fruit, they could be used as important parameters of horticultural maturity to inform growers to harvest Sri Lankan mango fruit at the optimum stage. In further work, mango fruits were ripened at 32oC for 4 days in order to better understand the temporal variation of major biochemical components during postharvest ripening. Mango cv. Malgova contained about three-fold higher organic acids than other cultivars tested, whilst cv. Willard had significantly higher glucose and ascorbic acid levels than cvs. Karutha Colomban and Malgova.
    [Show full text]
  • Victoria University Polytechnic Graduation Program March 2019
    VICTORIA UNIVERSITY POLYTECHNIC GRADUATION PROGRAM MARCH 2019 #vupolytechnic vupolytechnic.edu.au PRESENTING OF DIPLOMAS AND CERTIFICATES TABLE OF CONTENTS Our Value Proposition to Our Students 6 March 2019 and the Community 1 Victoria University, A Message from the Chancellor 2 Footscray Park Campus A Message from the Vice-Chancellor and President 3 A Message from the Vice President 4 Victoria University Polytechnic 5 100 Years Of Opportunity and Success 5 AT VU Polytechnic, family is everything 6 University Senior Executives 7 Victoria University Polytechnic Senior Leadership Team 7 Acknowledgement of Country 8 The University Mace – An Established Tradition 8 Academic Dress 9 Welcome to the Alumni Community 10 Social Media 11 Conferrals from Dec 2017 – Feb 2019 12 University Medal for Academic Excellence 29 Companion of the University 30 Honorary Graduates of the University 1987–2018 31 VU POLYTECHNIC GRADUATION PROGRAM MARCH 2019 OUR VALUE PROPOSITION TO OUR STUDENTS AND THE COMMUNITY Victoria University (VU) aims to be a great university of the 21st century by being inclusive rather than exclusive. We will provide exceptional value to our diverse community of students by guiding them to achieve their career aspirations through personalised, flexible, well-supported and industry relevant learning opportunities. Achievement will be demonstrated by our students’ and graduates’ employability and entrepreneurship. The applied and translational research conducted by our staff and students will enhance social and economic outcomes in our heartland communities of the West of Melbourne and beyond. Our graduates as employees and citizens will shape the industries in which they work and communities where they live. Healthier, smarter and more sustainable communities will result.
    [Show full text]
  • Press Galleries* Rules Governing Press
    PRESS GALLERIES * SENATE PRESS GALLERY The Capitol, Room S–316, phone 224–0241 Director.—S. Joseph Keenan Deputy Director.—Joan McKinney Senior Media Coordinators: Amy H. Gross Kristyn K. Socknat Media Coordinators: James D. Saris Wendy A. Oscarson-Kirchner Elizabeth B. Crowley HOUSE PRESS GALLERY The Capitol, Room H–315, phone 225–3945 Superintendent.—Jerry L. Gallegos Deputy Superintendent.—Justin J. Supon Assistant Superintendents: Ric Anderson Laura Reed Drew Cannon Molly Cain STANDING COMMITTEE OF CORRESPONDENTS Thomas Burr, The Salt Lake Tribune, Chair Joseph Morton, Omaha World-Herald, Secretary Jim Rowley, Bloomberg News Laurie Kellman, Associated Press Brian Friel, Bloomberg News RULES GOVERNING PRESS GALLERIES 1. Administration of the press galleries shall be vested in a Standing Committee of Cor- respondents elected by accredited members of the galleries. The Committee shall consist of five persons elected to serve for terms of two years. Provided, however, that at the election in January 1951, the three candidates receiving the highest number of votes shall serve for two years and the remaining two for one year. Thereafter, three members shall be elected in odd-numbered years and two in even-numbered years. Elections shall be held in January. The Committee shall elect its own chairman and secretary. Vacancies on the Committee shall be filled by special election to be called by the Standing Committee. 2. Persons desiring admission to the press galleries of Congress shall make application in accordance with Rule VI of the House of Representatives, subject to the direction and control of the Speaker and Rule 33 of the Senate, which rules shall be interpreted and administered by the Standing Committee of Correspondents, subject to the review and an approval by the Senate Committee on Rules and Administration.
    [Show full text]
  • RESEARCH REPORT NIFS-DATA Series
    JP0355031 Bibliography of Electron and Photon Cross Sections with Atoms and Molecules Published in the 20'hCentury - Argon - M. Hayashi (Received Jan. 17, 2003 NIFS-DATA-72 Jan. 2003 41 410 01 RESEARCH REPORT NIFS-DATA Series This report was prepared as a preprint of work perfon-ned as a collaboration research of the National Institute for Fusion Science (NIFS) of Japan. The views presented here are solely those of the authors. Ibis document is intended for iformation only and may be published in a journal after some rearrangement of its contents in the future. Inquiries about copyright should be addressed to the Research Information Center, National Insitute for Fusion Science, Oroshi-cho, Toki-shi, Gifu-ken 509-5292 Japan. E-mail: bunkenCa)nifs.acjp <Notice about photocopying> In order to photocopy any work from this publication, you or your organization must obtain permission from the following organizaion which has been delegated for copyright for clearance by the copyright owner of this publication. Except in the USA Japan Academic Association for Copyright Clearance (JAACC) 41-6 Akasaka 9-chome, Minato-ku, Tokyo 107-0052 Japan TEL:81-3-3475-5618 FAX:81-3-3475-5619 E-mail:naka-atsumuj.biglobe.nejp In the USA Copyright Clearance Center, Inc. 222 Rosewood Drive, Danvers, MA 01923 USA Phone: 978) 750-8400 FAX: 978) 750-4744 Bibliography of Electron and Photon Cross Sections with Atoms and Molecules Published in the 20thCentury - Argon * Makoto Hayashi (Gaseous Electronics Institute) A bibliography of original and review reports of experiments or theories of eectron and photon cross sections and also electron swarm data are presented for atomic or molecular species with specified targets.
    [Show full text]
  • Through December 1974) "
    N8S AlllDO TflSE^E NAri. INST OF STANDARDS & TECH R.I.C. All ^ „ ^ 100985292 W/Blbllography S^'l?Sl'1':t:i- of low ener QC100 .U57 V426;197§ C 2 NBS-PUB-C 1979 in Q NBS SPECIAL PUBLICATION 426 U.S. DEPARTMENT OF COMMERCE / National Bureau of Standards iDiiography or low tnergy tiectron and Photon Cross Section Data (through December 1974) " NATIONAL BUjREAU JDF STANDARDS The National Bureau of Standards^ was established by an act of Congress March 3, 1901. The Bureau's overall goal is to strengthen and advance the Nation's science and technology and facilitate their effective application for public benefit. To this end, the Bureau conducts research and provides: (1) a basis for the Nation's physical measurement system, (2) scientific and technological services for industry and government, (3) a technical basis for equity in trade, and (4) technical services to promote public safety. The Bureau consists of the Institute for Basic Standards, the Institute for Materials Research, the Institute for Applied Technology, the Institute for Computer Sciences and Technology, and the Office for Information Programs. THE INSTITUTE FOR BASIC STANDARDS provides the central basis within the United States of a complete and consistent system of physical measurement; coordinates that system with measurement systems of other nations; and furnishes essential services leading to accurate and uniform physical measurements throughout the Nation's scientific community, industry, and commerce. The Institute consists of the Office of Measurement Services, the Office of Radiation Measurement and the following Center and divisions: Applied Mathematics — Electricity — Mechanics —- Heat — Optical Physics — Center for Radiation Research: Nuclear Sciences; Applied Radiation — Laboratory Astrophysics — Cryogenics " — Electromagnetics " — Time and Frequency ".
    [Show full text]
  • Bibliography of Low Energy Electron and Photon Cross Section Data
    AlllOD =lflS3t,S NBS PUBLICATIONS '^*™iirainiI'i,?L?I^N°?5PS & TECH R.I.C. Gallagher, Alffi?5365 QC100 .U57 V4^!sU^pV^7^'^y^^l',PUB-C NBS SPECIAL PUBLICATION 426, Suppl. 1 U.S. DEPARTMENT OF COMMERCE / National Bureau of Standards Bibliography of Low Energy Electron and Photon Cross Section Data (January 1975 through December 1977) '426 Dl 1 NATIONAL BUREAU OF STANDARDS The National Bureau of Standards' was established by an act of Congress March 3, 1901 . The Bureau's overall goal is to strengthen and advance the Nation's science and technology and facilitate their effective application for public benefit. To this end, the Bureau conducts research and provides: (1) a basis for the Nation's physical measurement system, (2) scientific and technological services for industry and government, (3) a technical basis for equity in trade, and (4) technical services to promote public safety. The Bureau's technical work is performed by the National Measurement Laboratory, the National Engineering Laboratory, and the Institute for Computer Sciences and Technology. THE NATIONAL MEASUREMENT LABORATORY provides the national system of physical and chemical and materials measurement; coordinates the system with measurement systems of other nations and furnishes essential services leading to accurate and uniform physical and chemical measurement throughout the Nation's scientific community, industry, and commerce; conducts materials research leading to improved methods of measurement, standards, and data on the properties of materials needed by industry, commerce, educational institutions, and Government; provides advisory and research services to other Government Agencies; develops, produces, and distributes Standard Reference Materials; and provides calibration services.
    [Show full text]
  • Press Galleries *
    PRESS GALLERIES * SENATE PRESS GALLERY The Capitol, Room S–316, phone 224–0241 www.dailypress.senate.gov Director.—Laura Lytle Senior Media Relations Coordinators: Amy H. Gross Kristyn K. Socknat Media Coordinators: Elizabeth B. Crowley John E. Mulligan III Samantha J. Yeider HOUSE PRESS GALLERY The Capitol, Room H–315, phone 225–3945 Superintendent.—Annie Tin Deputy Superintendent.—Justin J. Supon Assistant Superintendents: Ric Anderson Laura Reed Drew Cannon Molly Cain STANDING COMMITTEE OF CORRESPONDENTS Siobhan Hughes, Wall Street Journal, Chairwoman Peter Urban, Stephens Media Group, Secretary Colby Itkowitz, Washington Post Kate Hunter, Bloomberg News Emily Ethridge, CQ Roll Call RULES GOVERNING PRESS GALLERIES 1. Administration of the press galleries shall be vested in a Standing Committee of Cor- respondents elected by accredited members of the Galleries. The Committee shall consist of five persons elected to serve for terms of two years. Provided, however, that at the election in January 1951, the three candidates receiving the highest number of votes shall serve for two years and the remaining two for one year. Thereafter, three members shall be elected in odd-numbered years and two in even-numbered years. Elections shall be held in January. The Committee shall elect its own chairman and secretary. Vacancies on the Committee shall be filled by special election to be called by the Standing Committee. 2. Persons desiring admission to the press galleries of Congress shall make application in accordance with Rule VI of the House of Representatives, subject to the direction and control of the Speaker and Rule 33 of the Senate, which rules shall be interpreted and administered by the Standing Committee of Correspondents, subject to the review and an approval by the Senate Committee on Rules and Administration.
    [Show full text]